Several of the p53 mutants identified in sebaceous carcinoma (Kiyosaki et al., 2010) are also found in prostate cancer and retain the ability to impair AR signaling, despite being mutations in the DNA-binding domain (Nesslinger et al., 2003). This evidence concerns the gene AR and sebaceous adenocarcinoma.